Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Globe Newswire (Mon, 9-Mar 8:30 AM ET)
Alliance Global Partners Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)
TipRanks (Mon, 9-Mar 7:38 AM ET)
Analysts Are Bullish on These Healthcare Stocks: Cooper Co (COO), Pelthos Therapeutics (PTHS)
TipRanks (Fri, 6-Mar 6:30 AM ET)
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Globe Newswire (Mon, 23-Feb 8:00 AM ET)
Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics
Business Wire (Thu, 15-Jan 4:10 PM ET)
Globe Newswire (Tue, 13-Jan 8:30 AM ET)
Pelthos Therapeutics Acquires Xeglyze (abametapir) Topical Treatment for Head Lice
Globe Newswire (Mon, 5-Jan 7:30 AM ET)
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
Globe Newswire (Tue, 23-Dec 5:57 PM ET)
Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
Pelthos Therapeutics trades on the AMEX stock market under the symbol PTHS.
As of March 10, 2026, PTHS stock price climbed to $25.31 with 1,111 million shares trading.
PTHS has a market cap of $81.89 million. This is considered a Micro Cap stock.
Last quarter Pelthos Therapeutics reported $7 million in Revenue and -$5.30 earnings per share. This beat revenue expectation by $527,200 and missed earnings estimates by -$4.63.
The top ETF exchange traded funds that PTHS belongs to (by Net Assets): VTI, VXF.
PTHS support price is $21.32 and resistance is $24.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTHS shares will trade within this expected range on the day.
